MRTX-1719
MRTX-1719 Basic information
- Product Name:
- MRTX-1719
- Synonyms:
-
- Benzonitrile, 2-[4-[4-(aminomethyl)-1,2-dihydro-1-oxo-6-phthalazinyl]-1-methyl-1H-pyrazol-5-yl]-4-chloro-6-(cyclopropyloxy)-3-fluoro-, (2R)-
- MRTX-1719,CRC,Histone Methyltransferase,NSCLC,Inhibitor,MTA,MRTX1719,MRTX 1719,inhibit,PRMT5
- 2-[4-[4-(Aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl]-1-methyl-5-pyrazolyl]-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
- (2R)-2-(4-(4-(Aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrile
- MRTX-1719, 10 mM in DMSO
- Navlimetostat
- BMS 986504
- navlimetostatum
- CAS:
- 2630904-45-7
- MF:
- C23H18ClFN6O2
- MW:
- 464.89
- Mol File:
- 2630904-45-7.mol
MRTX-1719 Chemical Properties
- Density
- 1.58±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Acetonitrile: Soluble
DMSO: Soluble - pka
- 11.37±0.40(Predicted)
- form
- Solid
- color
- White to light yellow
- InChIKey
- BZKIOORWZAXIBA-UHFFFAOYSA-N
- SMILES
- CN1N=CC(C2=CC=C3C(NN=C(CN)C3=C2)=O)=C1C1C(=C(Cl)C=C(OC2CC2)C=1C#N)F
MRTX-1719 Usage And Synthesis
Uses
Navlimetostat is a potent, orally active, selective PRMT5?MTA complex inhibitor, with IC50 of 3.6 and 20.5 nM for PRMT5?MTA and PRMT5. Navlimetostat binds to the PRMT5?MTA complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study[1][2].
Biological Activity
MRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC50 of less than 10 nM in PRMT5/MTA MTAPDEL SDMA cells[1].
in vivo
Navlimetostat (12.5-100 mg/kg/d for p.o., 21 day) reduces the tumor growth in Lu-99 orthotopic xenograft tumor models[2].
Pharmacokinetic Analysis [2]
| Model | Route | Dose (mg/kg) | Cltotal (mL/min/kg) | Vdss (L/kg) | t1/2 (h) |
| CD-1 mouse. | i.v. | 3 | 83 | 6.3 | 1.5 |
| Beagle dog | i.v. | 2 | 14 | 3.4 | 4.8 |
| Cynomolgus monkey | i.v. | 2 | 15 | 2.3 | 6.1 |
| Model | Route | Dose (mg/kg) | Cmax (ug/mL) | AUCinf (h*ug/mL) | F (%) |
| CD-1 mouse. | p.o. | 30 | 1.16 | 4.85 | 80 |
| Beagle dog | p.o. | 10 | 1.40 | 7.47 | 59 |
| Cynomolgus monkey | p.o. | 10 | / | / | 41 |
| Animal Model: | Lu-99 (an MTAP/CDKN2A-deleted human lung cancer cell line ) xenograft tumor models[2] |
| Dosage: | 12.5, 25, 50, and 100 mg/kg/d, 21 day |
| Administration: | Oral gavage |
| Result: | Reduced the tumor volume with 86% tumor growth inhibition (TGI) at 50 mg/kg and 88% TGI at 100 mg/kg. |
IC 50
PRMT5
References
[1] Targeting the genetic and immunological drivers of cancer.
[2] CHRISTOPHER R. SMITH*. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers[J]. Journal of Medicinal Chemistry, 2022, 65 3: 1749-1766. DOI: 10.1021/acs.jmedchem.1c01900
MRTX-1719Supplier
- Tel
- 028-86040038 13980902949;
- market@dingdangchem.com
- Tel
- 13771642864
- snhuyu_2008@126.com
- Tel
- 19938173342 19181793067
- 1486288711@qq.com
- Tel
- 17625585511
- 1580084073@qq.com
- Tel
- 15000803246 18149758185
- sales-cpd@caerulumpharma.com